Annika Loft

Medicine & Life Sciences

1. Fluorodeoxyglucose F18 100%
2. Positron Emission Tomography Computed Tomography 98%
3. Positron-Emission Tomography 74%
4. Hodgkin Disease 61%
5. 64Cu-DOTATATE 49%
6. Radiotherapy 42%
7. Urokinase Plasminogen Activator Receptors 36%
8. Neoplasms 35%
9. Squamous Cell Carcinoma of Head and Neck 21%
10. Neuroendocrine Tumors 21%
11. Neoplasm Metastasis 21%
12. Therapeutics 20%
13. Progression-Free Survival 20%
14. Prospective Studies 20%
15. Survival 20%
16. Recurrence 19%
17. Edotreotide 19%
18. Sarcoma 18%
19. Head and Neck Neoplasms 17%
20. 1,4,7-triazacyclononane-N,N',N''-triacetic acid 15%
21. 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane 13%
22. Brown Adipose Tissue 13%
23. Ga(III)-DOTATOC 13%
24. Drug Therapy 12%
25. Somatostatin Receptors 11%
26. Lung Neoplasms 11%
27. Uterine Cervical Neoplasms 11%
28. Endometrial Neoplasms 11%
29. Bone and Bones 10%
30. Biopsy 10%
31. Radiation 10%
32. Lymphoma 10%
33. Paintings 10%
34. Ovarian Neoplasms 10%
35. Vulvar Neoplasms 10%
36. Liraglutide 10%
37. Anus Neoplasms 10%
38. Tumor Burden 9%
39. Intensity-Modulated Radiotherapy 9%
40. Lymph Nodes 9%
41. Cutaneous T-Cell Lymphoma 9%
42. Glucagon-Like Peptide-1 Receptor 9%
43. Single Photon Emission Computed Tomography Computed Tomography 9%
44. Liver 9%
45. Tomography 9%
46. Melanoma 9%
47. Glucose 8%
48. Neck 8%
49. Electrons 8%
50. Multicenter Studies 8%